Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
Frontiers in Immunology
|
March 9, 2026
Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells
Alexandros Nianias, Afroditi Katsarou, Henk Jan Prins, et al.
Bio-Protocol
|
March 4, 2021
Protocol for Isolation, Stimulation and Functional Profiling of Primary and iPSC-derived Human NK Cells
Janine E Melsen, Maria Themeli, Monique M van Ostaijen-Ten Dam, et al.
International Journal of Molecular Sciences
|
January 27, 2021
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
Renée Poels, Esther Drent, Roeland Lameris, et al.
Stem Cell Reports
|
March 11, 2015
The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells
Fabiana Perna, Ly P Vu, Maria Themeli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells
Esther Drent, Renée Poels, Ruud Ruiter, et al.
Stem Cell Reports
|
January 21, 2020
iPSC-Based Modeling of RAG2 Severe Combined Immunodeficiency Reveals Multiple T Cell Developmental Arrests
Maria Themeli, Amiet Chhatta, Hester Boersma, et al.
Hemasphere
|
June 16, 2021
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma
Arwen Stikvoort, Jort van der Schans, Subhashis Sarkar, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 17, 2017
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent, Maria Themeli, Renée Poels, et al.
Hemasphere
|
July 14, 2025
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy
Jort J van der Schans, Paresh Vishwasrao, Renée Poels, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
Charlotte L B M Korst, Chloe O'Neill, Wassilis S C Bruins, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
Frontiers in Immunology
|
March 9, 2026
Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells
Alexandros Nianias, Afroditi Katsarou, Henk Jan Prins, et al.
Bio-Protocol
|
March 4, 2021
Protocol for Isolation, Stimulation and Functional Profiling of Primary and iPSC-derived Human NK Cells
Janine E Melsen, Maria Themeli, Monique M van Ostaijen-Ten Dam, et al.
International Journal of Molecular Sciences
|
January 27, 2021
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
Renée Poels, Esther Drent, Roeland Lameris, et al.
Stem Cell Reports
|
March 11, 2015
The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells
Fabiana Perna, Ly P Vu, Maria Themeli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells
Esther Drent, Renée Poels, Ruud Ruiter, et al.
Stem Cell Reports
|
January 21, 2020
iPSC-Based Modeling of RAG2 Severe Combined Immunodeficiency Reveals Multiple T Cell Developmental Arrests
Maria Themeli, Amiet Chhatta, Hester Boersma, et al.
Hemasphere
|
June 16, 2021
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma
Arwen Stikvoort, Jort van der Schans, Subhashis Sarkar, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 17, 2017
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent, Maria Themeli, Renée Poels, et al.
Hemasphere
|
July 14, 2025
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy
Jort J van der Schans, Paresh Vishwasrao, Renée Poels, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
Charlotte L B M Korst, Chloe O'Neill, Wassilis S C Bruins, et al.
Page
of 5